Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 839

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 2
Chunk 839
---
 a Director because of his well-balanced career
between finance and biopharmaceutical industries, especially leading M&A transactions while serving from executive positions with
his previous employer.

96

Dr. Joong Myung Cho became a Director of the Company upon the
Closing of the Business Combination. Dr. Cho has been Chairman and CEO of CG Pharmaceuticals, Inc. since October 2008 and previously
served as Chairman and CEO of Hwail Pharmaceuticals Co. Ltd. from August 2013 to December 2022. Dr. Cho is the founder
of Crystal Genomics and the former Chairman & President (July 2000 to March 2023). He has over 40 years of experience
in biopharmaceutical industry covering from discovery of novel pharmaceuticals through R&D and commercialization. Dr. Cho has
previously served as the executive Senior Vice President and Director of R&D Biotech Research Institute at LG Life Science (formerly
LG Chem.) from 1984 to 2000. During his tenure, biopharmaceutical R&D at LG became the leading life science company in Korea where
it grew from just a few research scientists to several hundred prior to his departure. He has successfully introduced 10 different recombinant
products such as growth hormones of human, bovine, and porcine, hepatitis B vaccine, interferon alpha and gamma, GM-CSF, EPO, etc. Moreover,
four drug candidates were licensed out to multinational pharmaceutical companies under his supervision and one of them is approved by
FDA (US). On the basis of such achievements, Dr. Cho has received many awards and acted as a member of governmental committees. He
received his Ph.D. from University of Houston and worked as a post-doc in Baylor College of Medicine. Dr. Cho is an author of
more than 80 publications in books and journals including Nature, and an inventor of more than 200 patents filed. Dr. Cho is well
qualified to serve as a Director because of long-standing career experiences both as a biotech entrepreneur and the R&D Head
of a major life sciences company in Korea (LG Group).

Number and Terms of Office of Officers and Directors 

We have seven directors and five officers. In accordance with Nasdaq
corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following
our listing on Nasdaq. The term of office of our initial directors will expire